Dynavax Technologies (DVAX) 15.27 $DVAX
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Marketwired - Sat Jun 11, 10:00AM CDT
Pivotal Phase 3 Data Show Investigational Two-Dose Hepatitis B Vaccine Provides a Significantly Higher Rate of Seroprotection Than an Approved Vaccine in Patients With Type 2 Diabetes
DVAX: 15.27 (-0.22)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.27 (-0.22), PACB: 7.51 (-0.02), AVXL: 7.73 (+0.15), PPHM: 0.40 (+0.01)
Dynavax to Present at Two Upcoming Investor Conferences
Marketwired - Wed May 18, 6:01AM CDT
BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows:
DVAX: 15.27 (-0.22)
Dynavax Technologies Down 16.5% Since SmarTrend Downtrend Call (DVAX)
Comtex SmarTrend(R) - Fri May 13, 1:38PM CDT
SmarTrend identified a Downtrend for Dynavax Technologies (NASDAQ
VAX) on April 27th, 2016 at $18.36. In approximately 2 weeks, Dynavax Technologies has returned 16.54% as of today's recent price of $15.32.
DVAX: 15.27 (-0.22)
Dynavax Technologies reports 1Q loss
Automated Insights - Mon May 09, 8:05AM CDT
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Monday reported a loss of $27 million in its first quarter.
DVAX: 15.27 (-0.22)
Dynavax Reports First Quarter 2016 Financial Results
Marketwire Canada - Mon May 09, 8:02AM CDT
BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.
DVAX: 15.27 (-0.22)
Does This Upstart Pose a Threat to GlaxoSmithKline?
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 7:40AM CDT
SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent...
DVAX: 15.27 (-0.22), GSK: 43.52 (+0.14)
Downgrade Alert for Dynavax Technologies (DVAX)
Comtex SmarTrend(R) - Fri Apr 29, 4:01AM CDT
Dynavax Technologies (NASDAQVAX) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $17.53 on volume of 1.1 million shares, above average daily volume of 901,000. Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
DVAX: 15.27 (-0.22)
Why Dynavex Technologies Shares Are Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 1:04PM CDT
SOURCE: DYNAVEX TECHNOLOGIES What: After the FDA said it needs more time to review its application for approval of HEPLISAV-B, shares of Dynavex Technologies Corp. are tumbling, down 12.6% at 1:00 p.m Wednesday. So what: The FDA is...
DVAX: 15.27 (-0.22)
Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016
Marketwired - Wed Apr 27, 6:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B(TM), Dynavax's investigational vaccine for immunization of adults against hepatitis B infection. In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) action date for HEPLISAV-B has been extended by three months to December 15, 2016.
DVAX: 15.27 (-0.22)
3 Biotech Stocks I'd Buy Right Now
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 21, 9:43AM CDT
Image Source: Celgene In case you haven't noticed, biotech stocks are finally on a roll again. After months of sliding downward, many are now mounting comebacks. While not every biotech stock is a winner, there are plenty of great picks. Here are...
DVAX: 15.27 (-0.22), JUNO: 27.33 (-0.48), CELG: 103.41 (-1.62)
Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101
Marketwired - Mon Apr 18, 3:02PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.
DVAX: 15.27 (-0.22)
Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)
Marketwired - Mon Apr 18, 3:02PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the leading vaccine, Engerix-B, in adults 18 to 70 years of age. These data were presented at the National Foundation for Infectious Diseases' (NFID) 19th Annual Conference on Vaccine Research (ACVR) in Baltimore, MD.
DVAX: 15.27 (-0.22)
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Marketwired - Sat Jun 11, 10:00AM CDT
Pivotal Phase 3 Data Show Investigational Two-Dose Hepatitis B Vaccine Provides a Significantly Higher Rate of Seroprotection Than an Approved Vaccine in Patients With Type 2 Diabetes
DVAX: 15.27 (-0.22)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.27 (-0.22), PACB: 7.51 (-0.02), AVXL: 7.73 (+0.15), PPHM: 0.40 (+0.01)
Dynavax to Present at Two Upcoming Investor Conferences
Marketwired - Wed May 18, 6:01AM CDT
BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows:
DVAX: 15.27 (-0.22)
Dynavax Technologies Down 16.5% Since SmarTrend Downtrend Call (DVAX)
Comtex SmarTrend(R) - Fri May 13, 1:38PM CDT
SmarTrend identified a Downtrend for Dynavax Technologies (NASDAQ
VAX) on April 27th, 2016 at $18.36. In approximately 2 weeks, Dynavax Technologies has returned 16.54% as of today's recent price of $15.32. DVAX: 15.27 (-0.22)
Dynavax Technologies reports 1Q loss
Automated Insights - Mon May 09, 8:05AM CDT
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Monday reported a loss of $27 million in its first quarter.
DVAX: 15.27 (-0.22)
Dynavax Reports First Quarter 2016 Financial Results
Marketwire Canada - Mon May 09, 8:02AM CDT
BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.
DVAX: 15.27 (-0.22)
Does This Upstart Pose a Threat to GlaxoSmithKline?
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 7:40AM CDT
SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent...
DVAX: 15.27 (-0.22), GSK: 43.52 (+0.14)
Downgrade Alert for Dynavax Technologies (DVAX)
Comtex SmarTrend(R) - Fri Apr 29, 4:01AM CDT
Dynavax Technologies (NASDAQ
VAX) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $17.53 on volume of 1.1 million shares, above average daily volume of 901,000. Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways. DVAX: 15.27 (-0.22)
Why Dynavex Technologies Shares Are Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 1:04PM CDT
SOURCE: DYNAVEX TECHNOLOGIES What: After the FDA said it needs more time to review its application for approval of HEPLISAV-B, shares of Dynavex Technologies Corp. are tumbling, down 12.6% at 1:00 p.m Wednesday. So what: The FDA is...
DVAX: 15.27 (-0.22)
Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016
Marketwired - Wed Apr 27, 6:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B(TM), Dynavax's investigational vaccine for immunization of adults against hepatitis B infection. In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) action date for HEPLISAV-B has been extended by three months to December 15, 2016.
DVAX: 15.27 (-0.22)
3 Biotech Stocks I'd Buy Right Now
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 21, 9:43AM CDT
Image Source: Celgene In case you haven't noticed, biotech stocks are finally on a roll again. After months of sliding downward, many are now mounting comebacks. While not every biotech stock is a winner, there are plenty of great picks. Here are...
DVAX: 15.27 (-0.22), JUNO: 27.33 (-0.48), CELG: 103.41 (-1.62)
Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101
Marketwired - Mon Apr 18, 3:02PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.
DVAX: 15.27 (-0.22)
Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)
Marketwired - Mon Apr 18, 3:02PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the leading vaccine, Engerix-B, in adults 18 to 70 years of age. These data were presented at the National Foundation for Infectious Diseases' (NFID) 19th Annual Conference on Vaccine Research (ACVR) in Baltimore, MD.
DVAX: 15.27 (-0.22)
